Pharma R&D in general includes too many drugs targeting the same pathways. I know many will say let the market differentiate the best in class (assuming they make it that far). However, too often there is only limited differentiation. Many companies still follow the money in a manner similar to the profusion of statin drugs during the 80's and 90's.
Market Data 
Markets 
AI
